We will highlight advances in modeling of CAR-T cells and T-cell engaging antibodies from the underappreciated lens of their shared mechanism of action, including pharmacokinetics, target engagement, cell pathophysiology and biodistribution. We will highlight vignettes on incorporating additional nuances of drug feature assessment and disease features in the modeling that could improve the translatability of such mechanistic models. We will also describe how integrated mechanistic modelling can capture the untapped potential of inter-indication translational (e.g. from oncology to immunology), ultimately guiding efficient design and informed decision making for more personalized treatment strategies with these immune therapies. Together, these mechanistic lessons lend to the development of a unified modeling framework for CAR-T cells and T cell engaging antibodies to help decode the principles that drive T cell therapy response.
Learning Objectives:
Upon completion, participants will be able to understand the complex mechanisms of action of CAR-T cells and T-cell engagers, and how they can be captured with a QSP modeling framework
Upon completion, participants will be able to define the synergies in inter-modality translation for CAR-T cells and T-cell engagers, which are currently underappreciated in the field
Upon completion, participants will be able to recognize the valuable potential for cross-translation between oncology and immunology that can be enabled via mechanistic modeling
.jpg "Peter Ashcroft, PhD (he/him/his) photo")